Pain perception among depressed heroin addict patients

2011 ◽  
Vol 26 (S2) ◽  
pp. 15-15
Author(s):  
E. Chkonia ◽  
V. Kenchadze ◽  
Z. Beria ◽  
N. Okribelashvili ◽  
G. Naneishvili ◽  
...  
Keyword(s):  
Atypical Antipsychotics ◽  
Pain Perception ◽  
Mood Stabilizers ◽  
Heroin Addict ◽  
Guilt Feeling ◽  
Efficient Treatment ◽  
Low Mood ◽  
Co Morbidity ◽  
Increased Sensitivity ◽  
Highly Correlated

There are an increased evidence of co-morbidity between pain, abnormal sensations and depression in heroin addict patients. Such conditions are usually treated by antidepressants, mood stabilizers and rarely by atypical antipsychotics.Investigation of heroin addict patients in post-abstinent state reviled that low mood, anxiety, tension and guilt feeling increased sensitivity toward pain, which mostly experienced as algetic, coenestetick and hypochondriacal sensations. Algetic symptoms highly correlated with psychopathology. Efficient treatment of psychopathological symptoms decreased pain. Atypical antipsychotic quetiapin monotherapy could be used for treating such conditions.

The treatment of cyclothymia

2017 ◽  
Author(s):  
Giulio Perugi ◽  
Giulia Vannucchi ◽  
Lorenzo Mazzarini
Keyword(s):  
Daily Life ◽  
High Sensitivity ◽  
Mood Stabilizers ◽  
Behavioural Treatment ◽  
Low Mood ◽  
Clear Cut ◽  
Cognitive Behavioural Treatment ◽  
Psychopharmacological Treatment ◽  
Cognitive Behavioural ◽  
Co Morbidity

The treatment of cyclothymia is problematic due to its rather complex clinical picture (early onset, lack of clear-cut episodes, high co-morbidity), a challenging patient–doctor relationship and a high sensitivity to medications. This chapter summarizes available evidence on pharmacological treatment, psychoeducation, and psychotherapy for cyclothymic patients. The management of cyclothymia should rely on integrated strategies. The psychopharmacological treatment has to follow the principle of ‘go slow and stay low’. Mood stabilizers should be the first option and antidepressants and antipsychotics should be used cautiously and for short periods of time to manage depressive, anxious, or hypomanic symptoms. Psychoeducation should be started from the beginning and is aimed to promote a better knowledge of the disorder and its effects on daily life as well as adherence to medications. The inclusion of individual psychotherapeutic treatments (eg, cognitive behavioural treatment) should also be considered.

scholarly journals Overweight and the use of psychiatric drugs in patients with mental disorders attended at psychosocial care center, Teresina, Piauí, Brazil

2016 ◽  
Vol 33 (4) ◽  
Author(s):  
Marize Melo Dos Santos
Keyword(s):  
Mental Disorders ◽  
Selective Serotonin Reuptake Inhibitor ◽  
Reuptake Inhibitor ◽  
Serotonin Reuptake ◽  
Atypical Antipsychotics ◽  
Mood Stabilizers ◽  
Selective Serotonin ◽  
Serotonin Reuptake Inhibitor ◽  
Psychiatric Drugs ◽  
Obese Class

Introduction: Psychopharmacology brought numerous benefits to people with mental disorders, although undesirable side effects have arisen, including weight gain.Objective: Identify the overweight frequency in individuals with mental disorders and its relation with the use of psychiatric drugs.  Material and methods: Cross-sectional study with patients with mental disorders of both sexes, older than 18 years. Body Mass Index (BMI) used to diagnose overweight (BMI > 25 kg/m2). Chi-square test of Pearson (c²) and Poisson regression were used for analytical statistics for association between variables.Results and discussion: the study involved 109 individuals. Overweight was found in 70.7% of the study population, 29.4% presented pre-obesity, 26.6% were obese class I, 8.3%, obese class II, and 6.4% obese grade III (morbid). The overweight prevalence was significantly higher among patients who used selective serotonin reuptake inhibitor antidepressants (PR = 1,42, 95% CI 1,12 to 1,80, p = 0,004), typical antipsychotics (PR = 1,43, 95% CI 1,13 to 1,80, p = 0,003), atypical antipsychotics (PR = 1,24, 95% CI 1,01 to 1,54, p = 0,045) and benzodiazepines (PR = 1,37, 95% CI 1,10 to 1,71, p = 0,004) when compared to those who used tricycle antidepressants ((PR=1,20, 95% CI 0,93 to 1,54, p=0,153) and mood stabilizers (PR=1,09, 95% IC 0,88 to 1,35, p=0,416) .Conclusion: High prevalence of overweight significantly higher among patients who used selective serotonin reuptake inhibitor antidepressants, typical and atypical antipsychotics and benzodiazepines.

Review of antidepressants in the treatment of behavioral and psychiatric symptoms in dementia (BPSD)

2014 ◽  
Vol 4 (4) ◽  
pp. 183-188 ◽  
Author(s):  
Whitney M. Buterbaugh ◽  
Todd Jamrose ◽  
Jonathon Lazzara ◽  
Lindsay Honaker ◽  
Christopher J. Thomas
Keyword(s):  
Adverse Effects ◽  
Current Literature ◽  
Atypical Antipsychotics ◽  
Psychiatric Symptoms ◽  
Mood Stabilizers ◽  
Behavioral Disturbances ◽  
Pharmacologic Treatments

Behavioral disturbances are commonplace among patients with dementia. Management of these symptoms has proved difficult.1,2 Currently, there are no FDA approved pharmacologic treatments for the treatment of BPSD.3 Traditionally, atypical antipsychotics have been used to treat behavioral disturbances despite modest efficacy and undesirable adverse effects.34,5 Because of the increase in mortality, there is a continued push to reduce antipsychotic utilization in this population.9,10 Thus, many clinicians are using alternative agents such as antidepressants and mood stabilizers to help treat BPSD, while avoiding using antipsychotics. The goal of this review is to review, analyze, and discuss the current literature available on the use of antidepressants to treat BPSD.

Differential Diagnosis of Borderline Personality Disorder from Bipolar Disorder

2010 ◽  
Vol 32 (3) ◽  
pp. 189-205 ◽  
Author(s):  
Gregory Hatchett
Keyword(s):  
Bipolar Disorder ◽  
Differential Diagnosis ◽  
Borderline Personality Disorder ◽  
Personality Disorder ◽  
Atypical Antipsychotics ◽  
Treatment Approach ◽  
Borderline Personality ◽  
Mood Stabilizers ◽  
Health Counseling ◽  
Dsm V

Many psychiatrists have reconceptualized borderline personality disorder (BPD) as a variant of bipolar disorder and, consistent with the treatment of bipolar disorder, emphasize the use of mood stabilizers and atypical antipsychotics in treatment. This change in diagnostic practice is unfortunate. BPD is a distinct diagnostic construct, and clients who fit this pattern require a fundamentally different treatment approach than what is typically recommended for bipolar disorder. The purpose of this article is to update counselors on the expansion of bipolar disorder in the psychiatric literature, present evidence for the validity of BPD, discuss strategies for the differential diagnosis of it from bipolar disorder, review proposed changes in DSM-V, and integrate the literature into a mental health counseling framework.

Maintenance Therapies in Bipolar Disorder: Focus on Randomized Controlled Trials

2005 ◽  
Vol 39 (8) ◽  
pp. 652-661 ◽  
Author(s):  
David J. Muzina ◽  
Joseph R. Calabrese
Keyword(s):  
Bipolar Disorder ◽  
Combination Therapy ◽  
Maintenance Therapy ◽  
Atypical Antipsychotics ◽  
Mood Stabilizers ◽  
Antidepressant Effect ◽  
Controlled Trials ◽  
Research Database ◽  
Concomitant Treatment ◽  
Rapid Cycling

Objective: Lithium remains the cornerstone of maintenance therapy for bipolar disorder despite growing use of other agents, including divalproex, lamotrigine, carbamazepine and the atypical antipsychotics. Lithium has the largest body of data to support its continued use as a prophylactic agent; however, most of this data comes from early studies that did not use contemporary analytic methods. Alternatives to lithium are needed because of the relatively high rate of non-response to lithium monotherapy and the drug's frequent side-effects. This article reviews available data with an emphasis on double-blind, placebo controlled studies that examine the efficacy of lithium and other putative mood stabilizers: carbamazepine, divalproex, lamotrigine and olanzapine. Method: The authors reviewed key literature using Medline searches using key words: bipolar disorder, controlled trials, mood stabilizer, lithium, lomotrigine, divalproex, olanzapine, carbamazepine. Results: Lithium remains the gold standard for overall preventative efficacy in bipolar disorder, especially to decrease manic or hypomanic relapse. Of the mood stabilizers that have marked prophylactic antimanic properties, lithium appears to possess the greatest antidepressant effect. Divalproexmay also prevent recurrent bipolar mood episodes but the relative lack of controlled maintenance studies makes this less certain. There now exists an extensive and well-designed research database supporting the use of lamotrigine in the acute and prophylactic management of bipolar I disorder. Lamotrigine offers a spectrum of clinical effectiveness that complements lithium, in that it appears to stabilize mood ‘from below baseline’ by preventing episodes of depression and has been shown to be effective in rapid-cycling bipolar II disorder. Carbamazepine may be a useful alternative to lithium, divalproex and lamotrigine, particularly for patients with a history of mood-incongruent delusions and other comorbidities, but controlled data is more equivocal and it may lose some of its prophylactic effect over time. Emerging data continue to support the growing use of atypical antipsychotics, particularly olanzapine. Conclusions: Any monotherapy for use as a maintenance therapy of bipolar disorder appears to be inadequate for long-term use in the management of the majority of patients with bipolar disorder. Combination therapy has become the standard of care in the treatment of bipolar disorder and particularly in patients with treatment-refractory variants such as those with rapid-cycling. The emerging consensus is that patients on monotherapy, if followed for sufficiently long periods, will eventually require concomitant treatment to maintain a full remission. There exists a need for controlled trials that use random assignment to parallel arms including combination therapy followed by data analyses that include both relapse rate and survival techniques.

scholarly journals Drug utilization study of antipsychotics among schizophrenia patients in a tertiary care teaching hospital: a retrospective observational study

2020 ◽  
Vol 9 (6) ◽  
pp. 971
Author(s):  
Sahana M. Mogali ◽  
Basavaraj C. Kotinatot
Keyword(s):  
Observational Study ◽  
Drug Utilization ◽  
Atypical Antipsychotics ◽  
Demographic Data ◽  
Tertiary Care ◽  
Mood Stabilizers ◽  
Retrospective Observational Study ◽  
Utilization Pattern ◽  
Drug Utilization Study ◽  
One Year

Background: Aim of the study was to evaluate the drug utilization pattern of antipsychotics in schizophrenia patients in a tertiary care hospital.Methods: A retrospective observational study was conducted over a period of one year. Demographic data and drug utilization pattern of antipsychotics was collected from the surveyed prescriptions. Using WHO prescribing indicators data was analysed. Results were expressed in percentage.Results: Out of 300 prescriptions analysed, males were 58% and females 42%. Majority of schizophrenia patients were in age group of 15 to 45 years 70.33%. Olanzapine 75% was most common antipsychotic drug prescribed followed by risperidone 10.7%. Haloperidol 9.6%, fluphenazine 3.7% and chlorpromazine 1% were the other antipsychotics prescribed. Atypical antipsychotics 85.7% were commonly prescribed than conventional ones 4.3%. Concomitant drugs prescribed were anticholinergics, antihistaminics, sedative-hypnotics, antidepressants, mood stabilizers, antiulcer drugs and vitamin B complexes. Average number of drugs prescribed per prescription 3.26.Conclusions: Nowadays atypical antipsychotics are preferred over conventional ones because of their less side effects. Drug utilization study helps in rational usage of drugs important for patient care.

Sign in / Sign up

Export Citation Format

Share Document